These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 21626347)

  • 1. Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases.
    Edlmayr J; Niespodziana K; Focke-Tejkl M; Linhart B; Valenta R
    Curr Top Microbiol Immunol; 2011; 352():121-40. PubMed ID: 21626347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.
    Focke M; Swoboda I; Marth K; Valenta R
    Clin Exp Allergy; 2010 Mar; 40(3):385-97. PubMed ID: 20210812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?
    Tulaeva I; Kratzer B; Campana R; Curin M; van Hage M; Karsonova A; Riabova K; Karaulov A; Khaitov M; Pickl WF; Valenta R
    Front Immunol; 2020; 11():1368. PubMed ID: 32733455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant allergy vaccines based on allergen-derived B cell epitopes.
    Valenta R; Campana R; Niederberger V
    Immunol Lett; 2017 Sep; 189():19-26. PubMed ID: 28472641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future.
    Valenta R; Campana R; Focke-Tejkl M; Niederberger V
    J Allergy Clin Immunol; 2016 Feb; 137(2):351-7. PubMed ID: 26853127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant allergens for immunotherapy.
    Valenta R; Niederberger V
    J Allergy Clin Immunol; 2007 Apr; 119(4):826-30. PubMed ID: 17335886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel vaccines for allergen-specific immunotherapy.
    Akinfenwa O; Rodríguez-Domínguez A; Vrtala S; Valenta R; Campana R
    Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):86-99. PubMed ID: 33369572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficiency of peptide immunotherapy for respiratory allergy.
    Incorvaia C; Montagni M; Ridolo E
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):831-7. PubMed ID: 26901667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches.
    Valenta R; Campana R; Marth K; van Hage M
    J Intern Med; 2012 Aug; 272(2):144-57. PubMed ID: 22640224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy.
    Crameri R
    Immunol Allergy Clin North Am; 2006 May; 26(2):179-89, v. PubMed ID: 16701139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA and mRNA vaccination against allergies.
    Scheiblhofer S; Thalhamer J; Weiss R
    Pediatr Allergy Immunol; 2018 Nov; 29(7):679-688. PubMed ID: 30063806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergen-related approaches to immunotherapy.
    Rolland JM; Gardner LM; O'Hehir RE
    Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract.
    Patel HD; Chambliss JM; Gupta MR
    Curr Allergy Asthma Rep; 2017 Aug; 17(9):63. PubMed ID: 28822054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell epitope-based allergy vaccines.
    Larché M
    Curr Top Microbiol Immunol; 2011; 352():107-19. PubMed ID: 21567311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic allergen modification in the development of novel approaches to specific immunotherapy.
    Mutschlechner S; Deifl S; Bohle B
    Clin Exp Allergy; 2009 Nov; 39(11):1635-42. PubMed ID: 19624521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Treatments for Allergy: Advances in Peptide Immunotherapy.
    Calzada D; Baos S; Cremades L; Cardaba B
    Curr Med Chem; 2018; 25(19):2215-2232. PubMed ID: 29205109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of engineered allergen-specific immunotherapy vaccines.
    Focke-Tejkl M; Valenta R
    Curr Opin Allergy Clin Immunol; 2012 Oct; 12(5):555-63. PubMed ID: 22885888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The immunological background of the allergen vaccines application].
    Rogala B
    Wiad Lek; 1999; 52(11-12):539-46. PubMed ID: 10745688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allergen immunotherapy: current and new therapeutic strategies.
    Rolland JM; Douglass J; O'Hehir RE
    Expert Opin Investig Drugs; 2000 Mar; 9(3):515-27. PubMed ID: 11060692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.